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Abstract
Background: Pandoraea spp. are recently discovered bacteria, mainly recovered from cystic fibrosis (CF) patients,
but their epidemiology and clinical significance are not well known. We describe an epidemic spread of Pandoraea
pulmonicola from 2009 in our CF center, involving 6 out of 243 CF patients.
Methods: Bacterial identification used amplified ribosomal DNA restriction analysis (ARDRA), MALDI-TOF mass
spectrometry (MALDI-TOF MS) and 16S rDNA gene sequencing. The clonal link between strains was assessed with
pulsed field gel electrophoresis (PFGE) using XbaI. Clinical data were gathered for all patients.
Results: The index case was chronically colonized since 2000. The main hypothesis for this bacterial spread
was a droplet cross-transmission, due to preventive measures not being strictly followed. Antibiotic
susceptibility testing revealed resistance to beta-lactams, ciprofloxacin and colistin. However, there was susceptibility
to trimethoprim-sulfamethoxazole. All patients were chronically colonized with Pseudomonas aeruginosa, and the
acquisition of P. pulmonicola resulted in chronic colonization in all patients. Three patients died, and two patients
remained clinically stable, whereas one patient had a decline in lung function.
Conclusions: This study, which is the first to describe an epidemic spread of P. pulmonicola, notes the potential
transmissibility of this bacterial species and the need for infection control measures.
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Background
Pandoraea spp. are non-fermentative aerobic Gram
negative bacilli first described in 2000 by Coenye et al.
[1]. Initially, the genus Pandoraea was comprised of five
bacterial species (Pandoraea apista, Pandoraea pulmoni-
cola, Pandoraea pnomenusa, Pandoraea sputorum and
Pandoraea norimbergensis). Since then, four other
unnamed genomospecies and four other named species
(Pandoraea thiooxidans, Pandoraea oxalativorans, Pan-
doraea faecigallinarum and Pandoraea vervacti) have
been characterized [2–4]. These bacteria are ubiquitous
in the environment and have been recovered from the
soil, sea, and drinking water [5, 6]. In humans, Pandoraea
spp. are mainly isolated from Cystic Fibrosis (CF) patients,
and may cause chronic lung colonization [7–9]. Several
Pandoraea species have been reported in CF patients.
P. apista was involved in an epidemic spread in six CF pa-
tients in Denmark in 2003 [10]. More recently, P. sputorum
was an agent of chronic CF lung colonization in Spain [8].
In addition to lung colonization, invasive infections due to
Pandoraea species were also reported, although mostly in
non-CF patients [11, 12]. However, a case of bacteraemia
due to Pandoraea sp. was described in a CF patient [13].
This study reports an epidemic spread of P. pulmonicola in
six patients attending our CF center and is the first descrip-
tion of an epidemic involving this bacterial species.
Methods
Patients
In 2008, P. pulmonicola was identified as a non-
fermentative Gram negative organism, responsible for
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chronic lung colonization that started in 2000 in one of
our CF patients. During 2009, five of the 243 patients at-
tending our CF center contracted P. pulmonicola. In
order to analyze the clinical impact of P. pulmonicola in
the 6 patients, the following data were collected: age,
sex, type of CFTR mutations, date of first P. pulmonicola
isolation, associated pathogens, best forced expiratory
volume in one second (FEV1) value per year, number of
intravenous antibiotic courses per year, clinical status,
transplantation and clinical outcome.
Microbiology
Microbiological analysis of sputa was performed by grow-
ing sputa aerobically on both usual media and Burkolderia
cepacia selective medium (BCSA) (Biomérieux, Marcy
l’Etoile, France). Bacteria that grew on the BCSA were used
for bacterial identification and antimicrobial susceptibility
testing (AST). Bacterial identification for each suspected
strain was performed using API 20NE strips (Biomérieux,
Marcy l’Etoile, France), molecular techniques including
amplified ribosomal DNA restriction analysis (ARDRA),
16S rDNA gene sequencing, and MALDI-TOF mass spec-
trometry (MALDI-TOF MS). ARDRA was completed as
previously described [14] with five restriction enzymes
(AluI, CfoI, DdeI, MspI, and XmnI). The gyrB gene was
amplified for further restriction analysis, according to
Coenye [15], using the P. apista LMG 16407 type strain as
a positive control. Moreover, the 16S rDNA-based species-
specific PCRs were performed as described by Coenye [16].
Identification with the 16S rDNA gene sequencing was
performed as previously described [17]. Sequence align-
ment used the NCBI/BLAST (www.ncbi.nlm.nih.gov/blast)
and BIBI (https://umr5558-bibiserv.univ-lyon1.fr/lebibi/
lebibi.cgi) programs. Sample preparation for MALDI-TOF
MS analysis was conducted using MicroFlex LT with the
Biotyper v2.3 database (Bruker Daltonics). Briefly, colonies
from overnight bacterial cultures were smeared onto the
target plate (1 spot per strain), and 1 μL of α-cyano-
hydroxycinnamic acid was added. For strain comparison,
one strain from each patient was tested with pulsed-field
gel electrophoresis (PFGE) using XbaI, as previously de-
scribed [18]. Antibiotic susceptibility was determined on
Mueller-Hinton agar plates (Bio-Rad, Marnes-la-Coquette,
France) using both the disk diffusion method with Bio-Rad
disks (Bio-Rad, Marnes-la-Coquette, France) and the
Epsilometer test (E-test) (Biomérieux, Marcy l’Etoile,
France) according to the guidelines of the “Comité d’anti-
biogramme de la société française de microbiologie”
(CASFM) 2013 for Burkholderia cepacia [19].
Results
The first identification of Pandoraea pulmonicola in our
CF center occurred in January 2008 in a 64-year-old
man (patient 1), who was previously considered
chronically colonized with Achromobacter xylosoxidans,
as detected by the API 20NE strip. This patient was also
chronically colonized with mucoid Pseudomonas aerugi-
nosa. The systematic recovery of this strain on the BCSA
and its full resistance to colistin (absence of inhibition
zone around a 50 μg disk) prompted the sending of one
isolate to the Observatoire Burkholderia cepacia (Hôpital
Purpan, Toulouse, France) for analysis. The strain was
analyzed by ARDRA, which resulted in genus level identi-
fication of Pandoraea sp.; however, it could not discri-
minate between P. apista and P. pulmonicola. Among the
16S rDNA based PCRs described by Coenye [16], a posi-
tive amplification was obtained with the primer pair
appuF-panR, specific for P. apista and P. pulmonicola.
However, the gyrB gene failed to be amplified. This strain
was also analyzed by MALDI-TOF MS to confirm that the
genus level identification of the Pandoraea sp. (log score
value >2) matched the reference strain Pandoraea sp [2]
65 RLT. This identification was achieved through 16S
rDNA gene sequencing. Sequence alignment of the 655 bp
amplicon using NCBI/BLAST (www.ncbi.nlm.nih.gov/
blast) and BIBI (https://umr5558-bibiserv.univ-lyon1.fr/
lebibi/lebibi.cgi) led to the identification of the strain as
P. pulmonicola with 99.8 % sequence identity (654/
655 bp) with P. pulmonicola strain CCUG 38759
(sequences NR_1151861 and AY268173 in NCBI and
BIBI, respectively) and P. pulmonicola strain LMG
18106 (sequences NR_028750.1 and AF139175 in NCBI
and BIBI, respectively, see the phylogenetic tree in
Fig. 1). Retrospective identification of previous isolates
from patient 1 recovered from 2000 to 2008 (50 sputum
samples) rectified the identification as P. pulmonicola
(misidentified as A. xylosoxidans) and was used to assess
whether patient 1 was chronically colonized with P. pul-
monicola. From March 2009 to December 2009, five
additional patients acquired P. pulmonicola. Demographic,
bacteriological and clinical data for the six patients are
summarized in Table 1. Concerning bacterial identifi-
cation, one strain from each patient was identified by
ARDRA, 16S rDNA gene sequencing and MALDI-TOF
MS, which had the same results as patient 1. In order to
analyze the clonality of the strains, one strain per patient
was used for PFGE analysis. All strains displayed the same
PFGE type, demonstrating a clonal link between strains
(Fig. 2). Antimicrobial susceptibility testing was performed
on one isolate per patient (recovered in 2009). All strains
involved in the epidemic spread (patient 1 strains in 2009,
and patient 2 to 6 strains) displayed the same antimicro-
bial susceptibility pattern with the same MIC values using
the E-test methods. According to the interpretative
standards for Burkholderia cepacia, the epidemic strain
was resistant to piperacillin (>256 μg/mL), piperacillin-
tazobactam (>256 μg/mL), ticarcillin-clavulanic acid
(>256 μg/mL), ceftazidime (>256 μg/mL), cefepime
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(>256 μg/mL), imipenem (>32 μg/mL), meropenem
(>32 μg/mL), ciprofloxacin (>32 μg/mL) and colistin
(>256 μg/mL). The strain was susceptible to trimethoprim-
sulfamethoxazole (0.5 μg/mL) and intermediate to rifam-
picin (8 μg/mL). MIC values for cefotaxime (3 μg/mL),
ceftriaxone (8 μg/mL) and tigecyclin (4 μg/mL) could
not be interpreted because no breakpoint values were
available.
Discussion
One of the patients attending our CF center was chron-
ically colonized with P. pulmonicola since 2000, and five
out of the 243 patients acquired this bacterium in 2009.
Among Pandoraea species, P. pulmonicola was already
reported in CF chronic lung colonization. This bacterial
species was also reported to be the most predominant
Pandoraea species among Irish CF patients [20]. Pheno-
typical characteristics of strains are consistent with the
initial description made by Coenye et al. [1], since all
strains displayed catalase and oxidase activity, polar mo-
tility and grew aerobically on usual media, such as
Mueller-Hinton agar and also on BCSA. Notably, all
strains recovered from patients 2 to 6 were non-
pigmented, except for a brown pigmented strain recovered
from patient 1 in 2008 and identified as P. pulmonicola by
MALDI-TOF MS. The API20NE results were not reliable
with an identity score of 58.9 % (T = 0.64) for the species
A. xylosoxidans and an identity score of 22.2 % for Alcali-
genes faecalis 2 (T = 0.6, biochemical profile: 0040476).
Biochemical identification of Pandoraea spp. was not
suitable because this genus is not included in the
API20NE database. This explains the misidentification of
the strain recovered from patient 1 prior to molecular
identification. Previous studies have reported the misiden-
tification of P. sputorum as A. xylosoxidans [11] and the
misidentification of other Pandoraea species as A. faecalis,
A. denitrificans, CDC IV C2 and Acinetobacter spp. [21].
ARDRA, as well as 16S rDNA-based PCRs, resulted in a
genus level identification of the Pandoraea sp., but could
not discriminate between P. apista and P. pulmonicola.
Interestingly, the gyrB gene restriction fragment length
polymorphism (RFLP), which had been shown to be a reli-
able identification method for Pandoraea spp., could not
be performed due to amplification failure of the gyrB gene
for all the strains. Coenye et al. also reported low amplifi-
cation of the gyrB gene from the three P. pulmonicola
strains tested in their study [15]. Neither the 16S rDNA-
based specific PCR proposed by Coenye et al. in 2001 [16]
nor the ARDRA test [14] were able to differentiate P. pul-
monicola from P. apista. Nevertheless, our 655 bp 16S
rDNA gene sequence displayed more identity with the P.
pulmonicola type strain LMG 18106 (99.8 %) than with
the P. apista type strain LMG 16407 T (98.9 %). Com-
paring this sequence with other available 16S rDNA
Pandoraea strain sequences using the blast2N program
(www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) resulted
in 99.8 % homology with P. pulmonicola LMG 18106 T,
99.7 % with P. pnomenusa LMG 18087 T, 99 % with P.
apista LMG 16407 T, 98.9 % with P. sputorum LMG
18819 T, and 98.4 % with P. norimbergensis LMG
Fig. 1 Phylogenetic tree based on the 16S rDNA sequence of our Pandoraea sp. epidemic strain. The tree was constructed using a neighbor-joining
method, and 1000 bootstrap by using MEGA5 (Molecular Evolutionary Genetics Analysis version 5.0.) software as previously described (21). Values
above the lines are bootstrap values expressed as percentages
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Table 1 Patients characteristics and clinical outcome
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years) 64 23 39 29 18 18
Sex M M M F M M
CFTR mutation 1717-1GA/2789 + 5GA F508del/F508del F508del/F508del F508del/F508del F508del/R553X F508del/F508del
Date of first P.
pulmonicola isolation
2000 March 2009 June 2009 October 2009 November 2009 December 2009
Associated pathogens mucoid P. aeruginosa mucoid P. aeruginosa mucoid P. aeruginosa mucoid P. aeruginosa S. aureus, mucoid.
P. aeruginosa, A.
xylosoxidans, A. fumigatus




Volume in 1 second
(FEV1) value per year
2009 25 45 33 43 47 61
2010 / 41 25 35 44 42
2011 / 40 20 / 42 41
2012 / 31 19 / / 59




2009 8 2 6 10 7 8
2010 / 3 5 3 8 5
2011 / 1 4 / 7 6
2012 / 3 6 / / 1
2013 / 0 3 / / 0









Clinical outcome Death (October 2009)
from severe comorbidities
Stable Decline in lung function Death (April 2010) from
post transplantation bacteremia
due to P. aeruginosa


















18379 T. MALDI-TOF MS found the closest match with
reference strain Pandoraea sp [2] 65 RLT (score value > 2
for all six strains). Interestingly, Pandoraea sp [2] 65 RLT
displayed 99.8 % sequence identity with Pandoraea pul-
monicola (accession number AF139175) and 99.5 %
sequence identity with Pandoraea pnomenusa (accession
number AY268170) (data provided by Bruker Daltonics).
These results were consistent with the 16S rDNA se-
quence identity obtained above. The results from ARDRA,
16S rDNA sequencing and MALDI-TOF MS indicated
that these methods should be used together in order to
achieve an accurate identification at the species level.
In our assay, the epidemic strain was resistant to colis-
tin, aminoglycosides, fosfomycin, pefloxacin, ciprofloxacin,
ticarcillin, ticarcillin-clavulanic acid, meropenem, ceftazi-
dime, and aztreonam, which was similar to previous re-
ports for other Pandoraea species [8, 10, 11]. Until 2003,
all P. pulmonicola strains recovered from patient 1 dis-
played a more susceptible phenotype with lower MIC
values to piperacillin (32 μg/mL), piperacillin-tazobactam
(24 μg/mL) and imipenem (3 μg/mL). This susceptibility
pattern is similar to the P. sputorum strain described by
Fernandez-Olmos et al. [8] with susceptibility to imipe-
nem (MIC value of 4 μg/mL) and piperacillin-tazobactam
(MIC value ≤ 16 μg/mL). Notably, patient 1 received
piperacillin-tazobactam for the first time in 2007 and imi-
penem for the first time in January 2009, after the strain
became resistant to these antibiotics. After 2003, all re-
covered strains from patient 1 displayed the same AST
pattern as the epidemic strain (resistance to piperacil-
lin, piperacillin-tazobactam and imipenem). Jørgensen
et al. already reported intermediate susceptibility to
ceftriaxone in P. apista strains [10]. Susceptibility to
trimethoprim-sulfamethoxazole was also reported in P.
sputorum strains [8].
Analyses of hospitalization periods for patients 1, 2, 3,
4, 5, and 6 are consistent with the chronological acquisi-
tion of P. pulmonicola (data not shown). In 2009, the
source patient was hospitalized eight times. The clonality
of the strains isolated from all six patients was assessed
by PFGE analysis. The main hypothesis to explain the
bacterial spread between patients is droplet cross-
transmission. In our center, all patients have to follow
standard precautions and are asked to use an alcohol
hand rub. Specific droplet cross-transmission preventive
measures consist in the use of respiratory masks for
patients chronically colonized with P. aeruginosa and
cohorting patients chronically colonized with the B. cepa-
cia complex. In 2009, the number of patients in our center
who were chronically colonized with P. aeruginosa was
150 out of 243 (61.7 %). The preventative measures were
not strictly followed, and the patients had several contacts
without respiratory masks, which is likely to have enabled
droplet cross-transmission of P. pulmonicola. However,
we cannot completely exclude an indirect droplet medi-
ated cross-transmission or the possibility of exposure to a
common bacterial source. Finally, by applying strict cross-
transmission prevention measures, i.e. segregation of colo-
nized patients in single hospitalization rooms with use of
gowns for medical staff, consultations in specific rooms
and on specific days, forbidden access to common areas,
use of respiratory masks and use of specific spirometers
with single use turbines and mouthpieces, the epidemic
spread was controlled. In our study, all patients were
chronically colonized with the mucoid P. aeruginosa, and
associated pathogens were found in two patients. It would
be interesting to determine whether chronic P. aeruginosa
colonization is a condition that facilitates the acquisition
and colonization of P. pulmonicola. All patients remained
chronically colonized with P. pulmonicola after the date of
first acquisition, which is consistent with previously de-
scribed data regarding the ability of this bacterial species
to chronically colonize lungs of CF patients. For example,
in 2009, P. pulmonicola was recovered from 4/4 sputa
(patient 2), 14/14 sputa (patient 3), 10/10 sputa (patient 4),
20/20 sputa (patient 5) and 6/6 sputa (patient 6). As for
patient 1, the total number of positive sputa was 50 since
the year 2000. The main features for all six patients con-
cerning the clinical outcomes after P. pulmonicola acquisi-
tion are summarized in Table 1. Three patients died
(patient 1, patient 4 and patient 5). Patient 1 died in
October 2010 from severe comorbidities. Patient 4 died in
the context of P. aeruginosa bacteraemia (P. pulmonicola
was not retrieved in blood cultures). Patient 5 died in May
2012 from multiple-organ failure one month after lung
and liver transplantation (blood cultures grew P. pulmoni-
cola, P. aeruginosa, and A. xylosoxidans). Several patients
displayed declined lung function (Patient 3, Patient 4 and
Patient 5). Two patients are clinically stable (patient 2 and
patient 6). Patient 6 had a lung transplantation in January
2012 and is still chronically colonized with P. pulmonicola










Fig. 2 Dendrogram of the percent similarity between XbaI-digested genomic DNAs from P. pulmonicola isolates
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role played by P. pulmonicola in declined lung function is
difficult to determine since it is associated with the chronic
colonization of P. aeruginosa. However, recent data re-
ported virulence of P. pulmonicola strains, mentioning
that P. pulmonicola strains were more virulent than other
Pandoraea species and could translocate through polar-
ized lung epithelia with an in vivo virulence comparable to
that of B. cenocepacia [21].
Conclusions
Our study notes the role of P. pulmonicola as an emer-
ging pathogen that can cause chronic lung colonization
in CF patients. Identification tools need to be accurate
and must be based on molecular techniques and
MALDI-TOF MS. Cross-transmission preventive mea-
sures also need to be strictly followed to avoid an epi-
demic spread. Hopefully, the use of whole genome
sequencing will provide significant additional informa-
tion concerning the virulence of P. pulmonicola.
Consent
Informed consent was obtained from the six patients
that were reported in this article. For this retrospective
observational study, ethics adherence was not required.
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